In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Amycretin | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 30 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 12 (12 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 31 · 22 active | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Amycretin | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 321 | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 541 | 83481717 |
|---|
| Adverse eventsWhole body | 99 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 11 | 185185 |
|---|
| Liver fat and liver functionLiver | 11 | 1361279 |
|---|
| Appetite and food intakeMetabolic and weight | 11 | 1129517 |
|---|
| PharmacokineticsPharmacology | 33 | 969231 |
|---|
| Receptor activity and mechanismPharmacology | 413 | 8250626 |
|---|
| MortalityWhole body | 22 | 504217 |
|---|
| Energy expenditure and thermogenesisMetabolic and weight | 11 | 211 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Amycretin differs from GLP-1 at 40 positions and carries 1 added group.
What is different
Liraglutide differs from GLP-1 at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 31 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S8,500 participantsest. 26 Oct 2026 to est. 16 Sept 2030
Cardiovascular Risk · Obesity
Novo Nordisk A/S5,610 participants11 May 2026 to est. 15 Aug 2029
Obesity · Heart Failure
Novo Nordisk A/S1,778 participants24 Aug 2026 to est. 20 Sept 2028
Type 2 Diabetes · Cardiovascular Risk
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Amycretin | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | −0.9% HbA1c change from baseline at week 36 · zenagamtide 0.4 mg Dose studied: 0·4 mg36 weeksn = 752026 | −1.48% HbA1c change · liraglutide 1.8 mg Dose studied: 1.8 mg once daily26 weeksn = 7762013 |
−0.9%
HbA1c change from baseline at week 36 · zenagamtide 0.4 mg
Dose studied: 0·4 mg36 weeksn = 752026
−1.48%
HbA1c change · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 7762013
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Amycretin | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in sds | No comparable result 4 randomized-trial results measure it in another way or another unit. | −0.22 SDS Estimated difference in BMI SDS Dose studied: 3.0 mg56 weeksn = 2512020 |
| PharmacokineticsPharmacologyCompared as: difference from placebo, in minutes | No comparable result 1 randomized-trial result measure it in another way or another unit. | 15 minutes tmax delay Dose studied: 1.8 mgn = 182011 |
|---|
| Liver fat and liver functionLiverCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −44% Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size. Dose studied: 1.8 mg/d26 weeksn = 722018 |
|---|
| Appetite and food intakeMental health and moodCompared as: difference from placebo, in meals/day | No randomized trial result 1 result from other study designs. | −1 meals/day Meal replacements per day difference Dose studied: 1.2 mg per dayn = 522015 |
|---|
| Receptor activity and mechanismNervous system and cognitionCompared as: difference from placebo, in proteins | No randomized trial result 4 results from other study designs. | 124 proteins Proteins modulated Dose studied: 3 mg daily5 weeksn = 202026 |
|---|
| Adverse eventsGastrointestinalCompared as: difference from placebo, in % | No comparable result 6 randomized-trial results measure it in another way or another unit. | 28% Serum lipase increase n = 9,3402017 |
|---|
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 21% Nausea · liraglutide 1.8 mg Dose studied: 1.8 mg once daily26 weeksn = 9112013 |
|---|
No comparable result
4 randomized-trial results measure it in another way or another unit.
−0.22 SDS
Estimated difference in BMI SDS
Dose studied: 3.0 mg56 weeksn = 2512020
No comparable result
1 randomized-trial result measure it in another way or another unit.
15 minutes
tmax delay
Dose studied: 1.8 mgn = 182011
No randomized trial result
1 result from other study designs.
−44%
Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size.
Dose studied: 1.8 mg/d26 weeksn = 722018
No randomized trial result
1 result from other study designs.
−1 meals/day
Meal replacements per day difference
Dose studied: 1.2 mg per dayn = 522015
No randomized trial result
4 results from other study designs.
124 proteins
Proteins modulated
Dose studied: 3 mg daily5 weeksn = 202026
No comparable result
6 randomized-trial results measure it in another way or another unit.
28%
Serum lipase increase
n = 9,3402017
No randomized trial result
1 result from other study designs.
21%
Nausea · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 9112013